The LIFE Trial

Losartan Intervention For Endpoint reduction in

hypertension study (LIFE)

Presented at the American College of Cardiology

51st Annual Scientific Session
Atlanta, GA

Dr Björn Dahlöf
for the LIFE Investigators

www. Clinical trial results.org

 LIFE: Study Design

Patients with hypertension (blood pressure 160-200/ 95-115 mm Hg)

and left ventricular hypertrophy

Losartan Atenolol
Angiotensin II antagonist Beta-blocker
Dose titrated to BP <140/90 mm Hg Dose titrated to BP <140/90 mm Hg

(n=4,605) (n=4,588)

Followed for >4 years - Mean follow-up 4.8 years

Cardiovascular death, MI, stroke

www. Clinical trial results.org

 LIFE: Primary Composite Endpoint
Composite of CV Death / MI / Stroke

P=0.021
15%
12.8%
11.0% Adjusted
Hazard
10% Ratio =
0.87

Rate 23.8/1,000 Rate 27.9/1,000

5% patient yrs patient yrs

n=508 n=588
0%
Losartan Atenolol

www. Clinical trial results.org

 LIFE: Individual Endpoint Results

Cardiovascular Death Myocardial Infarction Stroke

P=0.206 P=0.491 P=0.001
8% 8% 8%
Adjusted Adjusted Adjusted 6.7%
HR 0.89 HR 1.07 HR 0.75
6% 6% 6%
5.1% 5.0%
4.4% 4.3% 4.1%
4% 4% 4%

2% 2% 2%

0% 0% 0%
Losartan Atenolol Losartan Atenolol Losartan Atenolol

www. Clinical trial results.org

 LIFE: New-onset diabetes

P=0.001
10%

8% Adjusted
Hazard 7.0%
Ratio =
6% 0.75
5.2%

4% Rate 13.0/1,000 Rate 17.4/1,000

patient yrs patient yrs

2%

n=241 n=319
0%
Losartan Atenolol

www. Clinical trial results.org